Lupin, Mark Cuban’s Cost Plus Drugs and COPD Foundation boost COPD treatment access
In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost ... Read More
Lupin gets Health Canada approval for generic Spiriva for COPD treatment
Lupin has announced that its subsidiary in Canada, Lupin Pharma Canada has received approval from Health Canada to market a generic version of Spiriva (tiotropium ... Read More
Lupin bags UK approval for Lutio inhalation product for COPD treatment
Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic ... Read More